Thursday, 24 October 2019

Glenmark receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

20 June 2019 | News

It is a generic version of EVOCLIN® Foam, 1%, of Mylan Pharmaceuticals Inc.

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN® Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending April 2019, the EVOCLIN® Foam, 1% market achieved annual sales of approximately $17.0 million.

Glenmark’s current portfolio consists of 156 products authorized for distribution in the U.S. marketplace and 59 ANDA’s pending approval with the USFDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls